Is there value in Nextdc Ltd, Medibank Private Ltd, and Pro Medicus Limited shares?

Here's why Nextdc Ltd (ASX:NXT), Medibank Private Ltd (ASX: MPL) and Pro Medicus Limited (ASX:PME) hit their highest point all year this week.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While global stock markets continue to wobble in a perpetual will-they won't-they over questions like Greece exiting the Eurozone, the US raising rates, Australia cutting rates and many more issues, a number of quiet achievers have defied the gloom and gone on to set new highs.

Here's my take on whether they still offer value at today's prices:

Nextdc Ltd (ASX: NXT) – last traded at $2.70, up 8% for the year

Nextdc shares haven't really gone anywhere in the past 12 months, as investors are still waiting to see how the company's Data Centre (DC) business scales up. Performance has been strong however, with revenue rising 46%, utilisation up 59%, and a $6.4 million swing to a Net Profit After Tax of $0.6 million, up from a $5.8 million loss previously. Thanks to recent fundraising, Nextdc also has $225 million in cash and has works under way at its 'M1', 'S1', and 'C1' sites, as well as a sites' shortlist for upcoming projects B2 and M2.

It remains to be seen if Nextdc can earn attractive enough returns to justify the high capital expenditure required by its business model, but the company is scaling up nicely. The downside is that shares are highly priced, although there is also plenty of growth in the pipeline. Worthy of closer investigation by interested investors.

Medibank Private Ltd (ASX: MPL) – last traded at $2.89, up 22% for the year

Medibank shares hit a high of $2.97 earlier this week, with investors quite optimistic about the incoming CEO and recent premium increases. Certainly Medibank is an attractive business, with good recurring demand and significant macro tailwinds from healthcare demand and government initiatives (such as the Medicare levy surcharge). However, Medibank has been losing ground to competitors in its sector and has a number of company – and industry – specific issues to tackle.

With the uncertainty associated with a new CEO, as well as a highly-competitive marketplace, I would call Medibank a 'Hold' today.

Pro Medicus Limited (ASX: PME) – last traded at $3.70, up 165% for the year

Pro Medicus catapulted into the spotlight again recently after another significant contract win was announced, this time with Mercy Health in the US. If we double the half-year results to approximate full-year profits, shares trade at a lofty 60 times full-year earnings. However, interested investors should disregard the Price to Earnings (P/E) ratio and focus on the company's growth, which could just be getting started. Pro Medicus has announced a number of significant contract wins recently, and with management firmly focussed on the US market this number is likely to increase. With favourable foreign currency exposure thrown into the bargain, Pro Medicus is set for a significant increase in its earnings, making the P/E almost irrelevant.

As its product achieves a greater market presence, more contracts are likely to roll in, making Pro Medicus well worth a closer look by interested investors.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »